NCT00192166View on ClinicalTrials.gov

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

PHASE2CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

March 31, 2003

Study Completion Date

May 31, 2003

Conditions
Influenza
Interventions
BIOLOGICAL

CAIV-T

Trial Locations (1)

229899

Respiratory Medicine Service, Singapore

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY